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Imagine two individuals, both suering from 
severe liver damage. With excess fat molecules 
concentrated in the hepatic cells, their livers are 
in«amed and scarred. ese deteriorating livers are 
also supplementing the development of chronic 
obesity, diabetes, cardiovascular diseases, and 
hyperlipidemia. While one of these individuals is 
a middle-aged male with a long history of alcohol 
addiction and abuse, the other is only thirteen 
years old and has never consumed alcohol. is 
adolescent is suering from nonalcoholic fatty liver 
disease (NAFLD). 
e liver is not an isolated organ; it works 
in conjunction with almost every other system of 
the body, including the digestive, endocrine, and 
circulatory system. For instance, the liver regulates 
blood glucose levels, which is the body’s primary 
source of energy and fat. e liver metabolizes,
i.e. synthesizes and breaks down glucose and fat, 
depending on the body’s needs, and stores the 
excess energy temporarily in the form of glycogen 
and triglycerides (Manco, 2011). In the case of 
alcohol-induced fatty liver, alcohol disrupts the fat 
metabolism, causing an in«ux and accumulation of 
free fatty acids in the liver (Orman et al., 2013). 
NAFLD causes the same eect, driven primarily by 
obesity (Nobili et al., 2009).
In fact, NAFLD prevalence rates parallel 
the so-called “globesity” (global obesity) rates 
(Corte et al., 2012). In the United States alone, 
17% of children are considered overweight and 
obese by the Centers for Disease Control and 
Prevention (CDC); of these, 52% have NAFLD 
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Given that children have been exposed 
to an unhealthy lifestyle for a much 
shorter period than adults, genetics may 
play more of a dominant role in pediatric 
NAFLD prevalence than adult NAFLD; 
especially considering that in some cases, 
children have the disease despite optimal 
dietary and lifestyle habits (Nobili et al., 
2014). In fact, one study found that the 
immediate family members of children 
with NAFLD had a much higher 
percentage of liver fat content, with 
siblings at 9.3% and parents at 14% fat, 
than the family members of the children 
without the disease, whose siblings were 
at 2.7% and parents at 7% (Schwimmer 
et al., 2009). It is evident that NAFLD 
is impacted by an individual’s genetics; 
current research has identied multiple 
genes that play a role in its development 
(Dongiovanni et al., 2013). 
CONTEXTUAL FACTORS  
THAT FAVOR NAFLD AND  
THE TWO-HIT HYPOTHESIS
CHILDREN WITH NAFLD 
ALSO HAVE A THIRTEEN-
FOLD INCREASED RISK OF 
DEATH OR OF REQUIRING A 
LIVER TRANSPLANT 
suering from this disease represents 3%–13% of the 
total US adolescent population. NAFLD is dened by 
Anderson et al. (2015) as “the accumulation of fat in liver in the 
absence of excessive alcohol consumption or other known liver 
pathologies” (p. 2). e rst adult case was reported in 1980 by 
Ludwig, and in children by Moran in 1983 (Bozic et al., 2013). 
From 1994 to 2004, its prevalence rate increased to 62.84%, and 
within four years, it rose to 75.1% (Younossi et al., 2011). In 
2015, it is currently the leading cause of liver disease in children 
(Koot et al., 2015), with patients as young as three years of age 
(Manco et al., 2008). 
Since NAFLD is more common amongst Hispanic 
American than African American populations, 45% versus 
24% respectively, there may be a strong genetic predisposition 
toward developing the disease (Marzuillo et al., 2014). However, 
besides genetics, other factors can also signicantly contribute 
to the progression of the disease. ese are explained in terms 
of a double hit hypothesis, as shown in Figure 1. e rst hit 
refers to the accumulation of fat in liver cells. is sensitizes the 
liver to other factors, known collectively as the second hit, which 
aggravate the liver further, leading to in«ammation, scarring, 
and if left untreated, even cancer (Veena et al., 2014). e 
majority of pediatric NAFLD patients also show psychological 
symptoms (St-Jules et al., 2013), reporting a signicantly 
lower quality of life compared to healthy children, 72% versus 
83% respectively. eir symptoms include fatigue, depression, 
insomnia, and poor school performance (Kistler et al., 2010). 
Children with NAFLD also have a thirteen-fold increased risk 
of death or of requiring a liver transplant as compared to their 
healthy counterparts (Feldstein et al., 2009). Undoubtedly, 
we are letting one preventable and reversible global epidemic, 
obesity, exacerbate the spread of another preventable disease, 
advancing both to chronic and fatal conditions. is article 
examines how NAFLD develops in children and explores 
preventative measures and treatment options, including lifestyle 
modications, in order to present the best interventions for 
combatting the rapidly increasing rate of pediatric NAFLD. 
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FIGURE 1. The Progression of NAFLD
NAFLD does not refer to one particular disease with a set of symptoms. Rather, it is a spectrum 
of diseases, with three key stages. The earliest and most prevalent stage of NAFLD is called 
simple steatosis (Ozgur et al., 2013). This stage involves the accumulation of triglycerides in the 
liver cells due to an imbalance between the import and export of fatty acids (Nobili et al., 2009), 
without significant liver inflammation (Roberts, 2007). While simple steatosis is asymptomatic and 
reversible (Rafeey et al., 2009), if no action is taken to revert the liver’s condition, simple steatosis 
progresses to nonalcoholic steatohepatitis (NASH). At this stage, liver cells contain harmful amount 
of fat molecules, and there is significant inflammation with damaged and dead liver cells, which 
causes scarring (Aqel & Dibaise, 2015). If the liver cells do not regenerate at the same rate as they 
die, further scarring occurs, leading to cirrhosis (Ozgur et al., 2013), and in some cases, cancer 
(Boursier & Diehl, 2015). Unlike simple steatosis, NASH is not asymptomatic, although it may be 
reversible in some cases. However, once the disease has progressed to cirrhosis, the damage is 
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e most apparent and globally conspicuous genetic 
relationship of NAFLD is with the gene called PNPLA3, 
patatin-like phospholipase domain-containing protein 3 
(Lim et al., 2010), which is used to make an enzyme called 
adiponutrin (Park et al., 2015). Adiponutrin is primarily 
synthesized in liver and adipose (fat) tissue. In a healthy 
individual, it acts as a triglyceride synthase in adipose cells, and 
as a triglyceride hydrolase in liver cells. is means it can both 
synthesize and break down triglycerides, depending on the cell 
and the environmental factors that it is exposed to (Park et al., 
2015). In a NAFLD patient, a single nucleotide mutation, in 
which cytosine is substituted with guanosine, creates a dierent 
version of PNPLA3, a variant called rs738409-G allele, which 
codes for a modied adiponutrin protein that lacks its hydrolytic 
function (Marzuillo et al., 2014). is variant is correlated with 
a diet consisting of highly sweetened beverages and excess 
carbohydrates (Nobili et al., 2014). is adiponutrin variant 
continues to synthesize triglycerides in fat tissue, as it would 
in any healthy individual; however, it does not eectively break 
down proliferating triglycerides in the liver (Park et al., 2015). 
e accumulation of these fat particles causes severe steatosis, 
in«ammation, and brosis of the liver (Valenti et al., 2010). 
e PNPLA3-G variant and modied adiponutrin are most 
commonly found among the Hispanic population, which is also 
the population with the highest NAFLD prevalence (Marzuillo 
et al., 2014). Conversely, the population with the lowest rate 
of NAFLD (African Americans) have been found to carry a 
dierent variant of PNPLA3, called rs6006460-T-allele, which 
is associated with low hepatic fat (Pan & Fallon, 2014).
Marzuillo has hypothesized that there are also relationships 
between NAFLD and other genes, such as the glucokinase 
regulatory (GCKR) gene. e GCKR gene codes for a protein 
called glucokinase regulatory protein. is protein is responsible 
for mediating a liver enzyme called glucokinase (GCK), which 
carries out glucose and fat metabolism (Tan et al., 2013). In 
order to prevent synthesis of excess fatty acids, glucokinase 
regulatory protein binds to GCK and inhibits its activity. An 
Free Fatty Acids 
Long chains of carbon atoms that are derived 
from larger fat molecules
Gene 
A piece of information on DNA that results in 
a specific trait
Hyperlipidemia 
A condition in which there are high levels of 
fat molecules (lipids) in the blood
Lipid Peroxidation 
A process in which molecules with oxygen 
(known as free oxygen radicals) “steal” 
electrons from lipids, preventing their proper 
functioning
Mutation 
A permanent change in a part of the DNA
Nucleotides 
Organic molecules that make up the DNA
Oxidation  
Loss of electrons from a molecule or atom
Trait 
A physiological characteristic of an organism 
that may be inherited
Triglycerides 
Specific type of fat molecule, derived from 
glycerol, and three fatty acids
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NAFLD patient, however, has a dierent 
version of the GCKR gene, called 
rs780094 allele. is variant produces a 
dysfunctional GCKR, which is unable 
to inhibit GCK. Consequently, GCK 
continues to synthesize triglycerides, 
which accumulate in the liver cells (Petta 
et al., 2014). e prevalence of both the 
PNPLA3 and GCKR variants are lowest 
in the African American population. 
By contrast, GCKR variant is more 
prevalent in Han Chinese as compared 
to high PNPLA3 in Hispanic Americans 
(Lin et al., 2014). 
While such genes predispose an 
individual to NAFLD, the development 
of the disease can be described in terms 
of a two-hit hypothesis. e rst hit refers to the factors that lead 
to the accumulation of fat molecules in the liver, resulting in 
NAFLD (Nanda, 2004); specically, obesity, insulin resistance, 
and hyperinsulinemia (Marzuillo et al., 2015). ese factors, 
along with others like hypertension and glucose regulation, are 
categorized under metabolic syndrome (Alkhater, 2015). MtS, 
or metabolic syndrome, is an umbrella term used for a group 
of risk factors that lead to the development of cardiovascular 
diseases and type 2 diabetes mellitus (Schwimmer et al., 
2008). Considering NAFLD exacerbates the progression 
of cardiovascular diseases, it is believed to be the hepatic 
manifestation of metabolic syndrome (Alkhater, 2015). While 
all children with NAFLD have at least one other disease that is 
categorized under MtS, obese adolescents are at ve times the 
risk of the syndrome. is link between NAFLD and metabolic 
syndrome develops in early adolescence due to obesity-driven 
insulin resistance (Manco, 2011). 
Insulin resistance is dened as the body’s inability to 
lower blood glucose levels in the fasting state, despite the rise 
in insulin concentration in the blood (Mann et al., 2015).  In a 
healthy body, insulin triggers the muscle, fat, and liver cells to 
uptake glucose from the bloodstream and either metabolize it 
for energy or store it as glycogen. Simultaneously, it suppresses 
the production of free fatty acids in both adipose and liver 
tissue (Utzschneider & Kahn, 2006). e switch between 
metabolizing fat or glucose depends on the availability and 
demand of each macronutrient. In insulin-resistant patients, 
however, the body loses its ability to make that shift. Neither 
the adipose tissue nor the liver respond to insulin, glucose does 
not get absorbed by the cells (Lee et al., 2015), and free fatty 
acid synthesis continues in adipose and liver cells. Moreover, 
the adipose cells fail to expand in order to store the excess fat, 
which consequently gets delivered to the liver (Manco, 2011). 
Much like NAFLD and metabolic syndrome, fat accumulation 
and insulin resistance are a cyclical process. at is, the hepatic 
fat (Marzuillo et al., 2015), as well as the increased rate of 
triglyceride synthesis (Giorgio et al., 2013), exacerbates insulin 
Fibrosis 
Formation of excess fibrous connective 
tissue in an organ; scarring
Glucose 
A six carbon sugar that acts as a primary 
source of energy for the body
Glycogen 
A large sugar made up of multiple 
glucose molecules; this acts as the 
storage form of glucose/energy
Hyperinsulinemia 
A condition in which the levels of insulin in the 
blood are relatively higher than glucose levels
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resistance by preventing the activation of insulin receptors 
(Berardis & Sokal, 2014), worsening hepatic steatosis. 
Insulin sensitivity is 55% lower among obese adolescents 
with NAFLD as compared to healthy children (Lee et al., 
2015). Indeed, obesity is a major risk factor for NAFLD 
(Alkhater, 2015). Studies have shown that while 2–6% of the 
pediatric population has been diagnosed with the disease, this 
value signicantly increases to 20–50% for obese children. It 
is especially prevalent in pubertal children and adolescents 
than in pre-pubertal children (Ackam et al., 2013). At the 
onset of puberty, children go through hormonal imbalances, fat 
redistribution throughout the body, and a decrease in insulin 
sensitivity. Although most of these changes subside as a part 
of the maturation process (Cruz et al., 2005), the increase 
in blood insulin levels is sustained throughout adolescence 
(Loomba et al, 2009). Obesity, insulin levels, and triglyceride 
synthesis are connected in a cyclical process; an increase in one 
aggravates another.  
ese rst hit factors then branch into dierent 
pathologies, aecting the body as a whole. With proper 
treatment, the condition is reversible (Lim et al., 2010). e 
second hit, however, can perpetuate NAFLD and cause further 
liver damage. is can lead to nonalcoholic steatohepatitis 
(NASH), which makes reversal of the condition more 
di¥cult (Marzuillo et al., 2015). e second hit involves lipid 
peroxidation and in«ammatory cytokine activation, both of 
which are related to mitochondrial dysfunction (Giorgio et al., 
2013). Liver cells are rich in mitochondria, which are cellular 
organelles that use free fatty acids and oxygen to synthesize 
energy, carbon dioxide, and water (Basaranoglu et al., 2013). A 
dysfunctional mitochondrion, however, is unable to e¥ciently 
convert most of the oxygen into the required products, instead 
creating molecules known as reactive oxygen species, or ROS 
(Nanda, 2004). ese ROS negatively aect many cellular 
processes. ey carry out lipid peroxidation (Mylonas & 
Kouretas, 1999), oxidizing—and thus damaging—fatty acids 
(necessary for important cellular processes such as intracellular 
cell signaling and storage). When lipid 
peroxidation occurs at a high rate, 
oxidized fatty acids are synthesized at 
a toxic level. e damage from these 
molecules overwhelms the repair capacity 
of the cell, contributing to the fat stored 
in the liver cells. Moreover, in another 
cyclic process, lipid peroxidation causes 
further mitochondrial dysfunction, 
resulting in overproduction of oxygen 
species (Takahashi et al., 2010).
ROS also cause an imbalance 
in cytokine production (Marzuillo et 
al., 2015) by triggering the release of 
in«ammatory molecules from ectopic 
fatty tissue (Fitzpatrick et al, 2012), while 
simultaneously inhibiting the release of 
anti-in«ammatory molecules (Berardis 
& Sokal, 2014). ese in«ammatory 
cytokines include tumor necrosis factor-
alpha (TNF-α) and leptin. TNF-α not 
only enhances insulin resistance (Roberts, 
2007), but also activates a protein 
which binds to the DNA to induce the 
production of more ROS (Veena et al., 
Adipose Tissue 
Body fat, found under the skin
Cytokine 
Proteins responsible for cellular signaling. 
They are an active part of the immune system 
and regulate the maturation, growth, and 




A hormone produced and secreted by 
pancreas to regulate the synthesis and 
breakdown of carbohydrates and fats
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2014). Given a high concentration of 
ROS, TNF-α induces liver in«ammation, 
liver cell death, and brosis (Manco et 
al., 2007). Along with TNF-α, leptin 
synthesis is also high in obese patients 
with NAFLD. Leptin is a satiety 
cytokine, which the brain fails to respond 
to in cases of chronic obesity (Giorgio et 
al., 2013). Insensitivity to leptin prevents 
an individual from recognizing when 
they are full, and so they continue to eat 
and gain weight. Note that the damages 
caused by ROS—the oxidation of lipids, 
decrease in ATP production, and increase 
in in«ammatory cytokine release—are 
together categorized under the term 
oxidative stress. It is due to the collective 
eects of these events that the liver cells 
die (Ayala, 2014), thus causing 
in«ammation and scarring of the organ 
(Basaranoglu et al., 2013). 
Along with the aforementioned 
physiological changes, adolescents also 
gain increasing freedom to make their 
own decisions, including those about 
diet and physical activity. For many, these 
decisions result in switching to a diet of 
high calorie foods and a sedentary lifestyle 
(Giorgio et al., 2013). erefore, it is important to recognize 
the type of diet that promotes NAFLD progression. Children 
with NAFLD tend to eat a diet higher in total saturated fat and 
rened sugars as compared to both obese and lean children who 
do not have NAFLD (Mitchel & Lavine, 2014). Fructose, in 
particular, is associated with NAFLD, as patients with a higher 
intake of sugar-sweetened beverages are at an increased risk of 
developing the condition regardless of their age, sex, and BMI 
(Veena et al., 2014). Fructose is primarily metabolized in the 
liver, through a mechanism very similar to that of ethanol (Lim 
et al., 2010), which increases lipid synthesis. It also acts as a 
pro-in«ammatory mediator of NAFLD, contributing to liver 
in«ammation (Alkhater, 2015).
Fructose can also induce bacterial overgrowth and 
increased bacterial permeability in the small intestine, 
causing the movement of bacteria from the gut into the blood 
circulation (Michail et al., 2015). is increase in permeability 
leads to bacterial toxicity and the conversion of liver cells to 
myobroblasts, which release pro-in«ammatory molecules such 
as TNF-α (Alkhater, 2015). e toxins from the gut bacteria 
also activate the complement system (Zhan et al., 2010), 
further exposing liver to in«ammation (Lim et al., 2010). One 
of the main bacterial products involved in NAFLD is called 
lipopolysaccharide (LPS). As an active component of an 
endotoxin, LPS triggers a cascade of several enzymes involved 
in the in«ammatory pathway (Aqel & DiBaise, 2015). 
Before treatment can begin, a diagnosis must be made. According 
to many studies, this is a fairly di¥cult process primarily 
because the early stages of NAFLD are either asymptomatic or 
the symptoms are unrelated to the liver (Nanda, 2004). ere is 
also a general lack of non-invasive diagnostic tests (Anderson et 
al., 2015). A physical examination is of no help as it results in 
a diagnosis of obesity (Roberts, 2007). Consequently, NAFLD 
diagnosis is based on either elevated levels of aminotransferase 
PREVENTATIVE ACTIONS AND TREATMENT 
FOR IMPROVING CHILD HEALTH
Ectopic Fat 
The fat that accumulates in organs other 
than adipose tissue, e.g. in the liver, 
muscle tissues, pancreas and arteries
Fructose 
Fruit sugar made up of molecules 
of glucose and sucrose
Intracellular Cell Signaling 
Part of a communication system in the body 
that activates and coordinates cell actions
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(ALT), an enzyme that is secreted by damaged liver cells, or 
by decreased levels of adiponectin. However, even these results 
are not denitive diagnostic criteria. In fact, there is no proper 
threshold of ALT with respect to age and sex to indicate 
NAFLD (Anderson et al., 2015). e only sure way to diagnose 
NAFLD is to rst disprove all other possibilities (Hourigan et 
al., 2015), then carry out a liver biopsy, especially to distinguish 
between simple steatosis and NASH (Roberts, 2007). 
Once diagnosed, treatment for pediatric NAFLD must 
occur as soon as possible, with a focus on reversing steatosis and 
promoting healthy growth and development (Roberts, 2007). 
e best way known is through weight loss, which decreases 
the concentration of free fatty acids in liver, increases insulin 
sensitivity by metabolizing glucose rather than fat, and reduces 
the synthesis of ROS (Mitchel & Lavine, 2014). us, dietary 
changes and adequate exercise are considered the rst line of 
defense against progression of NAFLD to NASH (Nobili 
et al., 2009). A low glycemic index (GI) diet is appropriate 
for weight loss (Loomba et al., 2009), consisting of 50–60% 
carbohydrates, 23–30% fats, and 15–20% proteins. e intake of 
high fructose beverages must be reduced as greater amounts of 
sugar stimulate synthesis of fatty acids in the body, proliferating 
the fat in the liver (Manco et al., 2008). Since excess fructose is 
also associated with insulin resistance, steatosis, and oxidative 
stress, decreasing its consumption will signicantly improve 
liver health (Manco, 2011). Changing to a healthier diet can 
also signicantly decrease the blood levels of ALT (Nobili et al., 
2009). Some studies have recorded lower ALT and triglyceride 
levels after a twelve-month treatment with an omega-3 fatty 
acid DHA (Berardis & Sokal, 2014). Omega fatty acids, such 
as DHA and EPA, have been shown to reduce fat deposits by 
activating certain cellular pathways that induce breakdown of 
fatty acids and inhibit their synthesis (Manco et al., 2008).
Physicians and researchers agree that proper diet 
is signicant in reversing NAFLD in pediatric patients. 
However, it is important to cater the lifestyle modications 
to each individual; this serves several purposes. First, it 
improves compliance, which may be a 
zchallenge when working with children 
and adolescent patients. Second, dietary 
and physical requirements must be 
continuously reevaluated to account for 
the child’s developmental rate, changes in 
body weight, height, etc. (St. Jules et al., 
2013). It is extremely important that the 
child’s needs for growth are met (Berardis 
& Sokal, 2014), especially during puberty. 
Physical changes should not be the only 
aspect accorded importance. During this 
period, most children and adolescents are 
already sensitive about their body image 
and may have low self-esteem. erefore, 
overemphasizing the need for weight 
reduction should be avoided to prevent 
negative psychological eects (St. Jules et 
al., 2013). It is in fact harmful to lose a 
great amount of weight in a short period 
of time, as this may increase liver injury 
(Nobili et al., 2009). In order to ensure 
gradual weight loss, children should 
begin with moderate exercise like brisk 
Complement System 
Consists of small proteins that are synthesized 
in the liver, which complement antibodies and 
phagocytes in the immune system
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walking or swimming (Veena et al., 
2014). Although forty-ve minutes of 
aerobic exercise per day is recommended 
(Nobili et al., 2009) for treatment and as 
positive reinforcement (Roberts, 2007), 
more studies are required to determine 
the benets of exercise on its own, 
as well as with dietary changes (Deldin 
& Lee, 2013). 
Further research is also required 
in the pharmacological eld, since 
there is no drug treatment approved 
specically for NAFLD (Veena et al., 
2014). Pediatric NAFLD treatments 
are especially di¥cult because they 
must account for several factors, such 
as growth and development, hormonal 
changes, and rapid lifestyle modications. 
Any medication prescribed must be 
unresponsive towards the changes in 
an adolescent body (Berardis & Sokal, 
2014). For now, given that NAFLD 
progresses due to the cyclical process 
involving obesity, diabetes, insulin 
resistance, and oxidative stress, those 
are the pathologies targeted by most 
medicines (Nanda, 2004).  
e only weight loss medication approved by the FDA 
for pediatric use is Orlistat. Although this drug inhibits excess 
fat absorption, it also interferes with absorption of fat-soluble 
vitamins. Nonetheless, it may reverse steatosis and insulin 
resistance (Mitchel & Lavine, 2014).  Another medication, 
metformin, is well documented as a safe and eective treatment 
for diabetes (Loomba et al, 2009) and insulin resistance (Nanda, 
2004), and so is often prescribed to target that aspect of NAFLD. 
However, many studies have shown that although metformin 
helps to decrease insulin resistance, it does not improve liver 
condition any more than lifestyle changes (Manco, 2011). 
Another class of insulin sensitizers called thiazolidinediones 
have been shown to improve insulin sensitivity and reverse 
steatosis in adults (Nanda, 2004), but are not yet prescribed 
to children due to the lack of scientic support as well as the 
known side eects, which include weight gain, cardiovascular 
disease, and heart failure (Alkhater, 2015). 
Antioxidants such as vitamin E supplements are also 
considered to be a possible treatment option. In some cases, 
supplements have been shown to decrease the ballooning of 
the liver cells in NASH (Berardis & Sokal, 2014).  However, 
much like insulin sensitizers, there are either not enough 
cohort studies on their long term eects (Veena et al., 2014), 
or the few studies that have been done show no sign that 
vitamin E is more eective than lifestyle changes (Sarkhy et 
al., 2014). On the other hand, if vitamin E is administered with 
UDCA, an acid that deactivates bile to prevent the killing of 
liver cells, in conjunction with proper diet and exercise, ALT 
levels show improvement (Cho et al., 2012). In comparison, 
DHA, an omega-3-fatty acid, results in decreases in both the 
ALT and triglyceride levels (Alkhater, 2015). Probiotics have 
been found to have a similar eect (Berardis & Sokal, 2014); 
in fact, probiotics are being considered as highly valuable 
anti-in«ammatory agents that work by decreasing bacterial 
translocation (Mitchel & Lavine, 2014).
In extreme chronic cases, and as a last resort, surgery 
may be considered. Bariatric surgery and transplant is seen as 
Bile 
A fluid produced by the liver that is 
discharged into the small intestine to assist 
 in the digestion of ingested fats
Noninvasive 
Refers to treatment methods that do not 
require incisions, and lessen pain, healing 
time, and risk of infection
Steatosis 
Refers to accumulation of 
lipids inside a cell
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a treatment option for children whose lifestyle changes were 
unsuccessful or for those who were diagnosed in the chronic 
stage. ere are not enough studies on the long term safety of 
pediatric bariatric surgery and its eects on hepatic steatosis 
and in«ammation. However, it has been shown to improve ALT 
levels (Alkhater, 2015). ere are two types of surgeries, gastric 
banding and Roux-en-Y gastric bypass. Despite variable long-
term results, banding is believed to have the least amount of risk 
and is reversible. e gastric bypass procedure is believed to be 
more e¥cient, though it may lead to nutrient deciencies and 
protein malnutrition (Mitchel & Lavine, 2014).
Transplantation in NAFLD patients is often complicated 
by the conditions that come with the disease such as obesity, 
diabetes, and hyperlipidemia (Nanda, 2004). A condition 
called post-transplant metabolic syndrome is seen in some 
children who undergo liver transplants. Moreover, the 
immunosuppressive therapy that follows a transplant can lead 
to diabetes, hypertensions, cardiovascular diseases, and steatosis 
(Nobili & de Ville de Goyet, 2013). Prospective donors, 
especially those at risk for developing NAFLD themselves, 
must rst undergo liver biopsies (Mathur et al., 2007). 
  
 
Nonalcoholic fatty liver disease (NAFLD) is an increasingly 
prevalent condition that interferes with the proper growth 
and development of children. It has a wide array of causative 
factors, and its eects extend beyond the liver to the whole body. 
ere is a need for discussions about NAFLD at the public 
level, as fatty liver is mistakenly only associated with alcohol 
consumption. Obesity, heart disease, and hypertension are rarely 
associated with the liver, despite being strong contributors to 
the progression of NAFLD.  Since it is imperative that children 
with NAFLD be diagnosed as soon as possible, increasing 
knowledge on the disease will allow more cases to be caught in 
time. In fact, all children—especially those at risk of obesity, and 
those with a family history of fatty liver—should be screened 
for NAFLD on a regular basis. is highlights the dire need for 
further research to develop new diagnostic 
testing that is noninvasive, accurate, and 
less expensive.  
More long-term research is also 
needed to determine the e¥cacy of specic 
diets, supplements, and medications 
that are seen as options for NAFLD 
treatment. Currently, it is extremely 
important for NAFLD patients to be 
served by a multidisciplinary healthcare 
team. Dieticians, hepatologists, 
psychologists, and cardiologists need to 
evaluate the cases and be involved with 
the patient (Nobili et al., 2009). For 
pediatric patients, family involvement 
is also necessary to maintain nutritional 
knowledge and implement physical 
activity—along with clinical treatment.
CONCLUSION
Hepatologists 
Individuals who study the liver and 
its pathologies 
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